Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Previous close
$25.08
+$0.43 · +1.74%
Regular session · ET · Market data may be delayed.
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Day range
Current $25.08
52-week range
Current $25.08
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
60
Fair Value
Sentiment
72
Bullish
Risk
64
High Risk
Momentum
26
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Day range
Current $25.08
52-week range
Current $25.08
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 441.33M USD | 388.54M USD | 354M USD | 313.79M USD | 298.84M USD |
| Cost of goods sold | 170.88M USD | 139.76M USD | 124.83M USD | 111.27M USD | 101.32M USD |
| Gross profit | 270.45M USD | 248.78M USD | 229.18M USD | 202.52M USD | 197.51M USD |
| Research and development | 30.99M USD | 28.45M USD | 28.71M USD | 38.88M USD | 35.55M USD |
| Selling, general, and administrative | 212.72M USD | 192.38M USD | 208.98M USD | 157.44M USD | 169.77M USD |
| Operating expenses | 243.71M USD | 209.91M USD | 223.43M USD | 196.32M USD | 189.4M USD |
| Interest income | 763K USD | 1.47M USD | 1.08M USD | 147K USD | 79K USD |
| Interest expense | 26.58M USD | 34.28M USD | 25.3M USD | 18.22M USD | 16.89M USD |
| Depreciation and amortization | 22.46M USD | 24.21M USD | 23.08M USD | 22.44M USD | 23.98M USD |
| Operating income | 26.75M USD | 38.87M USD | 5.74M USD | 6.2M USD | 8.12M USD |
| Net income | 9.77M USD | −13.36M USD | −30.69M USD | −19.19M USD | −14.83M USD |
Company facts updated Sep 13, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$42.50
69.46% upsideCash distributions grouped by calendar year; partial years are marked.
$0.12
2015 complete year+11.6% since 2013
$0.1075
2,013
$0.1175
2,014
$0.12
2,015
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Dec 9, 2015 | $0.03Quarterly | Dec 11, 2015 | Dec 18, 2015 |
Dividend | Sep 9, 2015 | $0.03Quarterly | Sep 11, 2015 | Sep 18, 2015 |
Dividend | Jun 10, 2015 | $0.03Quarterly | Jun 12, 2015 | Jun 19, 2015 |
Dividend | Mar 11, 2015 | $0.03Quarterly | Mar 13, 2015 | Mar 20, 2015 |
Dividend | Dec 10, 2014 | $0.03Quarterly | Dec 12, 2014 | Dec 19, 2014 |
Dividend | Sep 10, 2014 | $0.03Quarterly | Sep 12, 2014 | Sep 19, 2014 |
Ex-dividend Dec 9, 2015
$0.03
Quarterly
Record Dec 11, 2015 · Payment Dec 18, 2015
Ex-dividend Sep 9, 2015
$0.03
Quarterly
Record Sep 11, 2015 · Payment Sep 18, 2015
Ex-dividend Jun 10, 2015
$0.03
Quarterly
Record Jun 12, 2015 · Payment Jun 19, 2015
Ex-dividend Mar 11, 2015
$0.03
Quarterly
Record Mar 13, 2015 · Payment Mar 20, 2015
Ex-dividend Dec 10, 2014
$0.03
Quarterly
Record Dec 12, 2014 · Payment Dec 19, 2014
Ex-dividend Sep 10, 2014
$0.03
Quarterly
Record Sep 12, 2014 · Payment Sep 19, 2014
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR73.65M0.07%107.03B USD0.06%$142.19+0.53%
Vanguard Morningstar Total Stock Market ETFVTI39.26M0.00%2.3T USD0.03%$376.31+0.82%
iShares Russell 2000 ETFIWM29.2M0.04%77.55B USD0.19%$288.89+0.41%
Vanguard Extended Market ETFVXF13.19M0.01%93.7B USD0.05%$237.76+0.68%
iShares S&P Small-Cap 600 Growth ETFIJT11.16M0.13%8.02B USD0.18%$166.46+0.48%
iShares Russell 2000 Growth ETFIWO10.83M0.07%14.32B USD0.24%$367.63+0.54%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM9.67M0.06%16.21B USD0.03%$55.31+0.55%
Vanguard Russell 2000 ETFVTWO6.89M0.04%17.4B USD0.06%$116.76+0.36%
iShares Core S&P Small-Cap ETFIJR
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares S&P Small-Cap 600 Growth ETFIJT
iShares Russell 2000 Growth ETFIWO
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Vanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.